Biotech-stock investing has one tough test for success - and it's about to get easier ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief U.S. Commercial Officer ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...